GoodRx Holdings, Inc. - 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2025. GoodRx Holdings, Inc. operates a consumer-focused digital healthcare platform in the United States, primarily offering prescription price comparison tools, subscription services (GoodRx Gold, RxSmartSaver+), and pharma direct advertising solutions. The company serves consumers, healthcare providers, pharmacies, and pharmaceutical manufacturers.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $796.9 million | $792.3 million |
| Net Income | $30.4 million | $16.4 million |
| Net Income Margin | 3.8% | 2.1% |
| Adjusted EBITDA | $270.5 million | $260.2 million |
| Adjusted EBITDA Margin | 33.9% | 32.8% |
| Cash and Cash Equivalents | $261.8 million | $448.3 million |
| Debt (Principal Outstanding) | $495.0 million | $500.0 million |
| Operating Cash Flow | $167.9 million | $183.9 million |
Material Changes vs. Prior Period
- Revenue Mix Shift: While total revenue increased slightly (1%), the composition changed significantly. Pharma Direct revenue grew 41% to $151.4 million, driven by expanded manufacturer partnerships. Conversely, Prescription Transactions revenue declined 6% to $544.0 million, and Subscription revenue fell 3% to $83.8 million.
- Consumer Metrics: Monthly Active Consumers (MAC) decreased 14% year-over-year, dropping from 6.6 million in Q4 2024 to 5.3 million in Q4 2025. Subscription plans declined from 684,000 to 674,000.
- Profitability: Net income nearly doubled due to improved operating leverage and cost management, despite the decline in core transaction volume.
- Acquisitions: The company acquired ScriptDrop (prescription delivery) and VCRx (prescription savings) in 2025, contributing approximately 1% to prescription transactions revenue.
Guidance, Outlook, and Risks
Management Commentary & Outlook: Management attributes the decline in prescription transactions to a changing retail pharmacy landscape, specifically store closures (e.g., Rite Aid bankruptcy) and volume reductions in integrated savings programs. They estimate a combined negative impact of $35.0 million to $40.0 million on 2025 revenue. The company is pivoting to position its Pharma Direct and Subscription offerings as primary growth drivers for 2026, anticipating near-term headwinds in transaction unit economics.
Key Risks and Contingencies:
- Regulatory Environment: The enactment of the "One Big Beautiful Bill Act" (OBBBA) in July 2025 reduced Medicaid funding and tightened eligibility. Additionally, the launch of the government-sponsored "TrumpRx.gov" platform in February 2026 presents an uncertain competitive landscape, though GoodRx is an integration partner.
- Legal Proceedings: The company has accrued a probable loss of $30.5 million related to a consumer privacy class-action lawsuit (NDCA Class Action Matter). Settlement negotiations are ongoing, with a preliminary approval motion denied in January 2026.
- Market Dynamics: Continued consolidation among PBMs and pharmacies, along with heightened renegotiations of reimbursement models, poses a risk to the prescription transactions business model.
Investor Verification Checklist
- Revenue Sustainability: Verify the trajectory of Pharma Direct growth to ensure it can offset the structural decline in Prescription Transactions revenue.
- Legal Exposure: Monitor the status of the $30.5 million accrued privacy lawsuit and potential for additional state-level litigation regarding discount card compliance.
- Competitive Impact: Assess the actual market share and consumer adoption of the new "TrumpRx.gov" platform and its effect on GoodRx's pricing competitiveness.
- Debt Covenants: Confirm continued compliance with the First Lien Net Leverage Ratio covenant (max 8.2x) under the $495 million term loan maturing in 2029.
- Consumer Retention: Analyze the effectiveness of new condition-specific subscription programs in reversing the 14% decline in Monthly Active Consumers.